Concerns Over Alternative Funding Programs for Patients
No Rare Disease Patient Should be Required to Use Non-FDA Approved Products
Across the healthcare landscape, there is an increasing concern about Alternative Funding Programs (AFPs) that aim to provide access to specialty care and rare therapies. While these programs may seem beneficial on the surface, they often impose significant barriers for patients seeking necessary medications. It is crucial to understand how AFPs operate and why they might jeopardize the health of rare disease patients.
AFPs typically require patients to navigate through complicated administrative processes to access their medications. This labyrinth of requirements can discourage patients from pursuing effective treatment options. Subsequently, many of these programs resort to importing drugs without the necessary FDA approval, exposing patients to significant health risks.
Understanding Alternative Funding Programs
An amicus brief, expressing the worries of various patient groups in the legal battle of Gilead Sciences vs. Meritain Health, highlights the serious health risks associated with these programs. According to this brief, the actions of various AFPs could have dire consequences for patient health, further emphasizing the need for FDA oversight on imported drugs.
Patient Groups Raise Concerns
The FDA has echoed these concerns through warning letters aimed at certain AFPs, underscoring that foreign drugs can pose significant health risks to users in the United States. The message is clear: the lack of FDA safety labeling and necessary patient information fundamentally compromises patient safety.
The Role of Third-Party Companies
According to insights from experts, such as Ashira Vantrees, Counsel at Aimed Alliance, AFPs are often intermediary entities working alongside employer-sponsored health plans to source alternative channels for patients' specialty drugs. Typical solutions include patient assistance programs (PAPs), international drug importation, and copay assistance.
However, these programs often categorize critical specialty medications, including rare or orphan therapies, as non-essential health benefits. This classification allows AFPs to impose unreasonable financial burdens on consumers. Patients may find themselves responsible for excessive coinsurance rates that do not contribute towards their deductible or annual out-of-pocket maximum, creating a financial disincentive to access their vital medications.
The Gilead Sciences Case
In the notable Gilead Sciences vs. Meritain Health case, the drug involved was obtained from another country, lacking the crucial safety and educational information required by U.S. standards. This scenario illustrates the potential dangers that patients are faced with when alternative funding comes into play.
The Call for Change
Michael Eging, the Executive Director of the Rare Access Action Project (RAAP), highlights the expectations patients have when they pay for insurance. "Patients and employers should have the assurance that the medications they are using are safe and properly labeled with FDA-approved information," he states. Eging condemns the coercive practices of some plans that push patients towards alternative funding sources rather than taking responsibility for their healthcare needs.
RAAP advocates for reforms that prevent the exploitation of patients who rely on these funding mechanisms and stresses the importance of protecting patient access to essential therapies. These proposed changes aim to eliminate the risks associated with AFPs that endanger patient safety solely to maximize profit margins.
Frequently Asked Questions
What are Alternative Funding Programs?
Alternative Funding Programs (AFPs) offer alternative routes for patients to access specialty medications, often involving non-FDA approved products.
Why are AFPs concerning for rare disease patients?
AFPs may expose patients to unapproved medications lacking necessary safety and labeling requirements, posing significant health risks.
What is the Gilead Sciences vs. Meritain Health case about?
This case highlights the dangers of sourcing drugs from countries without FDA approval, affecting patient safety and health information.
What is RAAP's stance on AFPs?
RAAP advocates against the practices of AFPs that coerce patients into unsafe alternatives and seeks regulatory changes to protect patient access.
How can patients ensure their medications are safe?
Patients can consult healthcare providers and current regulations to confirm that their medications are FDA-approved and safely sourced before use.
